Compounds of unstable DP IV-inhibitors
AssigneeProsidion Limited
InventorsHans-Ulrich Demuth, J?ouml;rn Schimdt, Torsten Hoffmann, Konrad Glund
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of unstable inhibitors of dipeptidyl peptidase IV (DP IV), which compounds have the general formula A—B—C, wherein A is an amino acid B is a chemical bond between A and C or is an amino acid, and C is an unstable inhibitor of DP IV. Such compounds are used in the treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy and sequelae of diabetes mellitus in mammals.
Claims13
Compounds of inhibitors of dipeptidyl peptidase IV (DP IV), which compounds have the general formula
- A—B—C,
- wherein
- A is an amino acid
- B is a chemical bond between A and C or is an amino acid, and
- C is an unstable inhibitor of DP IV, namely a dipeptidyl alkyl ketone derivative, with a fluoro alkyl ketone derivative being exempted from the dipeptidyl alkyl ketone derivatives, a dipeptidyl chloroalkyl ketone, dipeptidyl cyanide or a dipeptidyl pyridinium methyl ketone radical.
Compounds according to any one of the preceding claims, characterised in that the dipeptide group is Ile—Thia, Ile—Pyr, Val—Thia or Val—Pyr.
Compounds according to any one of the preceding claims, characterised in that the inhibitors are present in salt form.
Compounds according to any one of the preceding claims, characterised in that the inhibitors are present as organic salts such as acetates, succinates, tartrates or fumarates or inorganic acid radicals such as phosphates or sulphates.
Compounds according to any one of the preceding claims, characterised in that A—B is a dipeptide of formula Ile—Pro or Gly—Pro.
Pharmaceutical composition especially for oral administration, characterised in that it comprises at least one compound according to any one of the preceding claims optionally in combination with customary carriers or excipients.
Use of compounds or pharmaceutical compositions according to any one of the preceding claims in the preparation of a medicament for the temporally controlled in vivo inhibition of DP IV.
Dependencies are inferred from the claim text.